Amgen Inc.

Amgen Fremont Inc.

Medimmune Limited

Raffaella Faggioni

Orit Foord

Scott L Klakamp

Giorgio Senaldi

Larry L Green

Jaspal Singh Kang

Meina Liang

Palaniswami Rathanaswami

Kathy Manchulenko

Yen-Wah Lee

Ian Nevin Foltz

Mary Haak-Frendscho

John Stephen Babcook

Xiao Feng

Qiaojuan Jane Su

Jing Li

Brandon Higgs

Lorin Roskos

Koustubh Ranade

Katie Streicher

Kiran Ahluwalia

William Rees

Chris Morehouse

Robert W Georgantas, Iii

Amy K Schneider

Inna Vainshtein

Craig Pigott

Robert A Gasser, Jr

Jingjing Chen

Chris Kell

Rozanne Lee

Scott Klakamp

Meina L Liang

Richard May

Kathy Manchulencho

Quiaojuan Jane Su

The present invention relates to the use of the Chemokine (C&#x2014;C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

CCL20 as a predictor of clinical response to IL23-antagonists

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers

Antibodies directed to the antigen TNF&#x3b1; and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF&#x3b1;. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies directed to tumor necrosis factor and uses thereof

The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.

Fully human monoclonal antibodies to IL-13

Antibodies directed to the antigen IL-1&#x3b2; and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1&#x3b2;. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies against interleukin-1 &#x3b2;

Antibodies against interleukin-1&#x3b2;

Antibodies directed to tumor necrosis factor

Growing community of inventors

Pleasanton, CA, United States of America

Raffaella Faggioni